Epigenomics (company)
| Epigenomics AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | DE000A11QW50 |
| founding | 1997 |
| Seat |
Berlin , Germany
|
| management | Thomas Taapken CEO |
| Number of employees | 41 (2019) |
| sales | 1.1 million euros (2019) |
| Branch | biotechnology |
| Website | www.epigenomics.com |
| As of December 31, 2019 | |
The Epigenomics AG is a biotechnology company . The company is listed in the Prime Standard of the Frankfurt Stock Exchange and has specialized in the development of technologies for the detection of cancer. It develops early detection tests for colon , prostate and lung cancer as well as surveillance tests for colon and prostate cancer.
history
ONML Beteiligungs GmbH was founded in Frankfurt am Main on April 30, 1997 . On November 6, 1998 , the company changed its name to its current name and relocated to Berlin. Two years later, on February 25, 2000, the shareholders ' meeting decided to convert the GmbH into a stock corporation . In December of that year, Epigenomics acquired Orca Bioscience in Seattle. In September 2001, the company's founder, Alexander Olek , was voted “ Entrepreneur of the Year ”. In 2002 the company received the German Founder Award in the Visionary category and began its cooperation with Roche Diagnostics . Epigenomics went public on July 14, 2004. The subscription volume was around EUR 41.6 million with an issue price of EUR 9.00. In 2006 Roche Diagnostics ended its cooperation with Epigenomics. For Epigenomics this meant a drop in sales of three to four million euros annually, whereupon the share plummeted by 40 percent. The price fell to EUR 2.50 by the end of September, the lowest price since the IPO. At the same time, the company announced that it had entered into a non-exclusive strategic license and collaboration agreement with Abbott Molecular in early October, after the company secured patents for HeavyMethyl technology in the US and Europe.
Epigenomics AG announced in August 2009 that it has signed a non-exclusive license agreement with ARUP Laboratories, a leading provider of diagnostic tests, based in Salt Lake City, USA. ARUP receives the rights to use the DNA methylation biomarker Septin9 (mSEPT9) to develop a molecular colorectal cancer detection test. ARUP is the second laboratory in the US to license the mSEPT9 biomarker from Epigenomics. Abbott has released the CE marked IVD test under the brand name Abbott RealTime mS9 Colorectal Cancer .
In October 2009, Epigenomics AG launched Epi proColon , an early detection test for colon and lung cancer based on the detection of methylated SEPT9 DNA, and in July 2010 with Epi proLung , an early detection test for colorectal and lung cancer based on the detection of methylated SHOX2 DNA in serum . After Epi proColon received FDA approval for the US market in April 2016 , the stock market price, which had meanwhile fallen to below one euro, recovered. The only approved blood test to date for the early detection of colorectal cancer is being marketed in the USA by sales partner Polymedco.
Economic data
In 2006, Epigenomics AG had 106 employees, plus 36 employees in the subsidiary Epigenomics Inc. in Seattle . According to IFRS, the entire group had a balance sheet total of EUR 30.1 million and sales of EUR 3.5 million in 2006 , while Epigenomics-AG had total assets of EUR 32.6 million with sales of EUR 5, according to HGB accounting. 2 million euros. In the 2011 financial year, Epigenomics AG had 61 employees, 51 of them in Berlin and 10 in Seattle. They generated sales of EUR 1.44 million.
Web links
Footnotes
- ↑ a b Annual Report 2019. (PDF) In: epigenomics.com. Retrieved June 19, 2020 .
- ↑ Epigenomics AG Annual Report 2006, p. 7 ( Memento of the original dated May 17, 2008 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. at epigenomics.de
- ↑ Epigenomics AG ( Memento of the original from August 4, 2010 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. on deutscher-gruenderpreis.de
- ↑ In 2002, the German Founder Award was awarded to five companies for the first time ( Memento of the original from October 4, 2007 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. on deutscher-gruenderpreis.de
- ↑ Epigenomics share drops below issue price on stock market debut. Frankfurter Allgemeine Zeitung , July 19, 2004, accessed on May 2, 2016 .
- ↑ tagesspiegel.de, Roche goes - Epigenomics crashes , December 16, 2006 on tagesspiegel.de
- ↑ tagesschau.de, Epigenomics is making progress with cancer test ( memento of the original from October 16, 2007 in the Internet Archive ) Info: The archive link was inserted automatically and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. , October 4, 2007
- ↑ boerse-go.de, Epigenomics concludes license agreement with Abbott Molecular , September 26, 2007 as well as ad hoc announcement from Epigenomics on epigenomics.de
- ↑ tagesschau.de, Epigenomics is making progress with cancer test ( memento of the original from October 16, 2007 in the Internet Archive ) Info: The archive link was inserted automatically and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. , October 4, 2007 on boerse.ard.de
- ↑ Epigenomics AG licenses biomarkers for colorectal cancer blood tests to ARUP Laboratories, Inc. on finanznachrichten.de
- ↑ Epigenomics AG: Strategic partner Abbott introduces colorectal cancer blood tests in Europe and Asia / Pacific. (No longer available online.) Epigenomics AG, December 21, 2009, archived from the original on May 2, 2016 ; accessed on May 2, 2016 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.
- ↑ Laborjournal_2016_05. In: laborjournal-archiv.de. July 2, 2014, accessed May 16, 2016 .
- ↑ Dpa-Afx: DGAP-News: Epigenomics starts product sales of Epi proColon (R) in the USA (German). In: finanznachrichten.de. April 27, 2016, accessed May 16, 2016 .
- ↑ Annual Report of the Epigenomics Group 2006, pp. 42–43 ( page no longer available , search in web archives ) Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice. on epigenomics.com
- ↑ Annual Report of the Epigenomics Group 2006, pp. 64–65 ( page no longer available , search in web archives ) Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice. on epigenomics.com
- ↑ Epigenomics AG Annual Report 2006, pp. 1–3 ( Memento of the original from May 17, 2008 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. on epigenomics.com
- ↑ Annual Report 2011 ( Memento of the original from March 4, 2016 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. at epigenomics.de (PDF; 3.1 MB)
